Laboratory of Food Safety, College of Food Science and Engineering, Ocean University of China, Qingdao 266003, China.
Food Funct. 2021 Mar 21;12(6):2750-2759. doi: 10.1039/d0fo03039b. Epub 2021 Mar 8.
Tropomyosin (TM) is the most important allergen in shrimps that could cause food allergy. Glycation is reported to be effective in reducing TM allergenicity and produce hypoallergen; however, up to now, there are very few reports on the potential of hypoallergenic glycated TM (GTM) as allergen immunotherapy for shrimp TM-induced food allergy. This study investigated the glycation of TM-produced hypoallergen and the immunotherapeutic efficacy of GTM + Al(OH) as potential allergen immunotherapy. Compared to TM, the TM glycated by glucose (TM-G), maltotriose (TM-MTS), maltopentaose (TM-MPS) and maltoheptaose (TM-MHS) had weaker allergy activation on mast cells and mouse model as a hypoallergen. However, the TM glycated by maltose (TM-M) insignificantly affected the allergenicity. In addition, the GTM absorbed into Al(OH) could be efficacious as potential allergen immunotherapy, particularly for the TM glycated by the saccharides having larger molecular size (e.g., TM-MHS), which could provide preclinical data to develop GTM + Al(OH) as a candidate immunotherapy for shrimp allergic patients.
肌球蛋白（TM）是虾类中最重要的过敏原，可引起食物过敏。据报道，糖基化可有效降低 TM 的致敏性并产生低致敏性；然而，迄今为止，关于低致敏性糖基化 TM（GTM）作为虾 TM 诱导的食物过敏变应原免疫治疗的潜在性的报道很少。本研究探讨了 TM 产生的低致敏性的糖基化以及 GTM + Al(OH)作为潜在变应原免疫治疗的免疫治疗功效。与 TM 相比，由葡萄糖（TM-G）、麦芽三糖（TM-MTS）、麦芽五糖（TM-MPS）和麦芽七糖（TM-MHS）糖基化的 TM 作为低致敏原对肥大细胞和小鼠模型的过敏激活作用较弱。然而，由麦芽糖（TM-M）糖基化的 TM 对致敏性的影响不显著。此外，被 Al(OH)吸收的 GTM 可以作为潜在的变应原免疫治疗有效，特别是对于由分子大小较大的糖基化的 TM（例如 TM-MHS），这可以为开发 GTM + Al(OH)作为虾过敏患者的候选免疫疗法提供临床前数据。
